Login / Signup

Pharmacogenomics for Clinical Trials of COVID-19 Medicines: Why Is This Important Now?

Semra ŞardaşVural Özdemir
Published in: Omics : a journal of integrative biology (2021)
Keyphrases
  • clinical trial
  • coronavirus disease
  • sars cov
  • phase ii
  • clinical decision support
  • adverse drug
  • respiratory syndrome coronavirus
  • open label
  • double blind
  • randomized controlled trial
  • phase iii
  • emergency department